🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Bone Health in Adults With Duchenne Muscular Dystrophy: A Survey on Osteoporosis, Fractures and Treatment.

Recruitingn/aAges 18 Years - 44 YearsMaleIstituto Giannina Gaslini
NCT07890883 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background and Rationale Duchenne muscular dystrophy (DMD) is a genetic disorder caused by mutations in the dystrophin gene, resulting in progressive muscle weakness and multiple complications, including respiratory and cardiac impairment, osteoporosis (OP), and fragility fractures (FF). Bone fragility is a major concern, as lower-limb fractures may accelerate the loss of independent ambulation and complicate daily care. Despite increased life expectancy, bone health in adults with DMD remains insufficiently investigated. This study aims to address this knowledge gap and improve the understanding and management of skeletal complications in this population. Objectives The study aims to: (1) determine the prevalence of fragility fractures in adults with DMD; (2) identify childhood and adolescent risk or protective factors affecting adult bone health; (3) collect data on fracture treatmen

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria - Study Group (DMD Patients) 1. Genetic or histological diagnosis of Duchenne muscular dystrophy (DMD). 2. Age over 18 years. 3. Willingness to participate in the study and provision of written informed consent. Exclusion Criteria - Study Group (DMD Patients) 1. Current enrollment in another clinical study. 2. Inability to undergo dual-energy X-ray absorptiometry (DXA) due to severe kyphoscoliosis. 3. Previous surgery for scoliosis. 4. Severe respiratory failure, defined as the need for non-invasive ventilation (NIV) 24 hours per day or the presence of a tracheostomy. 5. Severe cardiomyopathy, defined as a left ventricular ejection fraction (LVEF) below 30%. 6. Severe intellectual disability (IQ below 45) and inability to perform functional assessments.
💊

What it tests

  • Not listed
📍

Where

15 sites
Centro Malattie Neuromuscolari dell'età Evolutiva, Bologna
Bologna, Italy
Associazione La Nostra Famiglia Eugenio Medea IRCCS, Bosisio Parini
Bosisio Parini, Italy
Associazione La Nostra Famiglia Eugenio Medea IRCCS, Conegliano
Conegliano, Italy
IRCCS Istituto Giannina Gaslini
Genova, Italy
Dipartimento di Scienze Cliniche e Sperimentali, Università di Brescia
Gussago, Italy
Azienda Universitaria Policlinico G. Martino
Messina, Italy
Fondazione IRCCS Istituto. Neurologico "C. Besta", Milano
Milan, Italy
Università degli Studi di Milano Statale
Milan, Italy

…and 7 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy